Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matter
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- FDA Drug Safety Communications
- Region
- USA
- Scope
- Regulatory
- Published
- July 24, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA Drug Safety Communications
Scope: Regulatory
Related coverage
More related coverage
Working for DHSC
We offer a varied, exciting, challenging and rewarding working environment.
Meningococcal B (MenB) time limited vaccination offer: eligibility flow chart
Guidance for health professionals delivering the time-limited MenB vaccination offer on the eligible...
Learning Support Fund 10th edition: 2026 to 2027
Information for academic authorities and students on pre-registration healthcare programmes in the 2...
Learning Support Fund guidance
Information for academic authorities and students on pre-registration healthcare programmes that pro...